Felix Biotechnology Inc.
Felix Biotechnology
- UEI
- Y3JNYYQ5YHA6
- CAGE
- 8JL70
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- felixbt.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercialization -… | National Institute of Allergy and Infectious Diseases | $784,424 | |
| Microfluidics platform for rapid, high-throughput screening of therapeutic bacteriophages based on patient bacterial… | National Institute of General Medical Sciences | $628,822 | |
| Sbir phase i: leveraging machine learning to enable generalized phage therapy for pulmonary infections | National Science Foundation | $256,000 |
About Felix Biotechnology Inc.
Felix Biotechnology Inc. is a company focused on creating programmable therapies to protect against antimicrobial resistance. They are developing phage therapies, which utilize bacteriophages (viruses that infect bacteria) as an alternative to traditional antibiotics. Their work aims to advance the use of phages for treating multi-drug resistant bacterial infections and preventing foodborne illnesses.
Through several federal grant awards from agencies like the National Institutes of Health (NIH) and National Science Foundation (NSF), Felix Biotechnology has worked on projects to engineer and enhance phage therapies. This includes developing tools to genetically modify phages for improved traits like broader host range, thermostability, and persistence at infection sites (NIH grant). They are creating a microfluidics platform for rapid, high-throughput screening of therapeutic phages based on patient bacterial isolates (NIH grant). Additionally, they have leveraged machine learning techniques to identify candidate phages against new or emerging bacterial pathogens in the lungs for treating pulmonary infections (NSF grant). Felix's work focuses on advancing phage-based therapeutics toward FDA approval and commercialization by overcoming limitations in phage engineering and host range.
Quick answers
What is Felix Biotechnology Inc.'s UEI?
Felix Biotechnology Inc.'s Unique Entity ID (UEI) in SAM.gov is Y3JNYYQ5YHA6.
What is Felix Biotechnology Inc.'s CAGE code?
Felix Biotechnology Inc.'s CAGE code is 8JL70.
What is Felix Biotechnology Inc.'s primary NAICS code?
Felix Biotechnology Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Felix Biotechnology Inc. registered in SAM.gov?
Felix Biotechnology Inc.'s SAM.gov registration expired on June 14, 2024.
What is Felix Biotechnology Inc.'s most recent federal award?
Felix Biotechnology Inc.'s most recent federal grant award is Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercialization -… (R41AI165185), from National Institute of Allergy and Infectious Diseases, on July 22, 2022.
On GovTribe
See Felix Biotechnology Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors